Skip to content

Biodesix, Inc. BDSX Total Equity

Total Equity at other companies

NeoGenomics logo
NeoGenomicsNEO
$828.76M-6.7%
Veracyte logo
VeracyteVCYT
$1.34B+12.5%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$216.34M+13.6%
Personalis, Inc. logo
Personalis, Inc.PSNL
$254.77M+22.9%
Guardant Health logo
Guardant HealthGH
-$181.07M+27.8%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$416.41M+27.7%

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s total equity?
Biodesix, Inc. (BDSX) reported total equity of $9.13M in Q1 2026.
How has Biodesix, Inc.'s total equity changed year-over-year?
Biodesix, Inc.'s total equity decreased by 17.4% year-over-year, from $11.06M to $9.13M.
What is the long-term trend for Biodesix, Inc.'s total equity?
Over 5 years (2020 to 2025), Biodesix, Inc.'s total equity has grown at a -43.1% compound annual growth rate (CAGR), from $41.17M to -$2.47M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.